Graft-versus-host disease (GVHD): General review
DOI:
https://doi.org/10.55677/IJCSMR/V4I3-05/2024Keywords:
donor, host, hematopoietic cell, cytokine, inflammation, transplantation, immune systemAbstract
Graft-versus-host disease (GVHD) is one of the major complications and source of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT) procedure. GVHD divided into two types, acute GVHD, and chronic GVHD. Traditionally as is known, acute GVHD accruing 3 months (100 days) after HCT, and the chronic GVHD accruing after 3 months (over 100 days) after HCT.
Generally, the most common symptoms of GVHD development: skin can be presented with rare rush, biopsies can show dyskeratotic keratinocytes. Liver presented with damage to the bile ducts and elevation of bilirubin levels. Lung's damage, bronchiolitis. Endoscopy of the anterointernal can show damage to the cecum, ileum, and colon. In addition, damage to the upper intestinal system.
Traditionally GVHD prophylaxis protocol consisted immunosuppression agents as calcineurin inhibitors such as Tacrolimus or Cyclosporine. In case of GVHD development, the standard first-line therapy of GVHD is corticosteroids (systemic and topical) including immunosuppression agent.
References
Pidala, J., Sarwal, M., Roedder, S. et al. Biologic markers of chronic GVHD. Bone Marrow Transplant 49, 324–331 (2014).
https://doi.org/10.1038/bmt.2013.97
Madan Jagasia, Mukta Arora, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 2012; 119 (1): 296–307. doi: https://doi.org/10.1182/blood-2011-06-364265
Rima M. Saliba, Marcos de Lima, Sergio Giralt, et al. Hyperacute GVHD: risk factors, outcomes, and clinical implications. Blood 2007; 109 (7): 2751–2758. doi: https://doi.org/10.1182/blood-2006-07-034348
Mahasweta Gooptu, Joseph Harry Antin. GVHD Prophylaxis 2020. ront. Immunol., 07 April 2021. Volume 12 –2.
https://doi.org/10.3389/fimmu.2021.605726
Harris, A.C., Ferrara, J.L.M. and Levine, J.E. (2013), Advances in predicting acute GVHD. Br J Haematol, 160: 288-302.
https://doi.org/10.1111/bjh.12142
Toubai, T., Sun, Y., & Reddy, P. (2008). GVHD pathophysiology: is acute different from chronic. Best Practice & Research Clinical Haematology, 21(2), 101-117.
https://doi.org/10.1016/j.beha.2008.02.005
Ball, L., Egeler, R. & on behalf of the EBMT Paediatric Working Party. Acute GvHD: pathogenesis and classification. Bone Marrow Transplant 41 (Suppl 2), S58–S64 (2008). https://doi.org/10.1038/bmt.2008.56
Jacobsohn, D.A., Vogelsang, G.B. Acute graft versus host disease. Orphanet J Rare Dis 2, 35 (2007). https://doi.org/10.1186/1750-1172-2-35
Holtan, S.G., Yu, J., Choe, H.K. et al. Disease progression, treatments, hospitalization, and clinical outcomes in acute GVHD: a multicenter chart review. Bone Marrow Transplant 57, 1581–1585 (2022). https://doi.org/10.1038/s41409-022-01764-w
Ho, Vincent T., and Corey Cutler. "Current and novel therapies in acute GVHD." Best Practice & Research Clinical Haematology 21.2 (2008): 223-237. https://doi.org/10.1016/j.beha.2008.02.009
Corey S. Cutler, John Koreth, Jerome Ritz; Mechanistic approaches for the prevention and treatment of chronic GVHD. Blood 2017; 129 (1): 22–29. doi: https://doi.org/10.1182/blood-2016-08-686659
Laura F. Newell, Shernan G. Holtan; Acute GVHD: think before you treat. Hematology Am Soc Hematol Educ Program 2021; 2021 (1): 642–647. doi: https://doi.org/10.1182/hematology.202100030
Messina, C., Faraci, M., de Fazio, V. et al. Prevention and treatment of acute GvHD. Bone Marrow Transplant 41 (Suppl 2), S65–S70 (2008). https://doi.org/10.1038/bmt.2008.57
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 International Journal of Clinical Science and Medical Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
